Also known as Stenabolic, SR9009 has been developed by Scripps Research Institute under the leadership of professor Thomas Burris.
As mentioned beforehand, SR9009 is a synthetic Rev-Erb ligand, which is taken orally. This is a very unique compound. By stimulating the Rev-Erb protein, SR9009 has the ability to greatly influence a lot of regulatory mechanisms in the human body. For instance, it can affect the circadian rhythms, lipid and glucose metabolism, fat-storing cells, as well as macrophages. Hence, Stenabolic will allow the user to lose fat and drastically increase endurance, both of which are very desirable effects for an athlete.
